Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOESTRIN 21 1/20 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Oral contraceptive therapy
Prevention of pregnancy (FDA-approved)
One tablet orally once daily for 21 days, then 7 days off. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 8-11 hours (terminal half-life; steady-state achieved after 5-10 days); Ethinyl estradiol: 13-27 hours (terminal half-life; significant interindividual variability due to enterohepatic recirculation).
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone is metabolized by CYP3A4 and reduction, conjugation (sulfation and glucuronidation).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50% (as metabolites, primarily glucuronide conjugates of norethindrone and ethinyl estradiol); Fecal: ~35% (via bile); Urinary recovery of unchanged drug is minimal (<1%).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~61% bound to albumin and SHBG; Ethinyl estradiol: ~97-98% bound to albumin (not to SHBG).
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 2-4 L/kg; Ethinyl estradiol: 2-4 L/kg (indicating extensive tissue distribution and high lipophilicity).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone ~64% (due to first-pass metabolism); Ethinyl estradiol ~45% (range 30-60%, with significant first-pass conjugation to sulfate and glucuronide).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; consider alternative contraception.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily for 21 days, 7 days off).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women. No specific geriatric dosing studies; use lowest effective dose if considered, but generally avoid due to increased thromboembolic risk.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use COCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI),Hepatic neoplasia risk,Ocular lesions (e.g., retinal thrombosis),Carbohydrate metabolism alterations,Elevated blood pressure,Gallbladder disease,Depression,Interactions with enzyme-inducing drugs (e.g., rifampin, anticonvulsants)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Current or past history of thromboembolic disorders or cerebrovascular disease,Significant liver disease or liver tumors (benign or malignant),Known or suspected estrogen-dependent neoplasia (e.g., breast cancer),Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Headache with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Cigarette smoking in women >35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. Grapefruit juice may increase estrogen levels; consider avoiding large amounts. Alcohol is not contraindicated but may affect liver metabolism. Consult with your healthcare provider.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy category X. Contraindicated in pregnancy. Use during first trimester associated with cardiovascular defects, limb reduction defects, and neural tube defects. Exposure in second and third trimester increases risk of fetal feminization in male fetuses, vaginal adenosis and cervical cancer in female fetuses. No known risk in third trimester for congenital anomalies.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk. Estrogen and progestin may reduce milk production and quality. M/P ratio not established. Use during breastfeeding not recommended. Alternative contraception advised until weaning.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy. No dose adjustments applicable; discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Loestrin 21 1/20 contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. It is a low-dose monophasic oral contraceptive. For missed pills, follow standard CDC guidelines: if one pill is missed, take it as soon as remembered; if two or more are missed, consider backup contraception. The 21-day regimen has a 7-day pill-free interval. Patients with breakthrough bleeding should be counseled that this is common in the first few cycles. Use with caution in patients with a history of hypertension, migraine with aura, or thromboembolic disorders.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time for 21 days, then none for 7 days.,If you miss a pill, take it as soon as you remember. If you miss two or more, use backup contraception (e.g., condoms) for 7 days.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,This medication does not protect against sexually transmitted infections (STIs).,Do not smoke while taking this medication, especially if over age 35, as it increases risk of serious cardiovascular events.,Seek medical attention if you experience severe abdominal pain, chest pain, headache, eye problems, or leg pain/swelling.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOESTRIN 21 1/20 vs AFIRMELLE, answered by our medical review team.
LOESTRIN 21 1/20 is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOESTRIN 21 1/20 and AFIRMELLE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOESTRIN 21 1/20 is: One tablet orally once daily for 21 days, then 7 days off. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOESTRIN 21 1/20 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOESTRIN 21 1/20 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. Use during first trimester associated with cardiovascular defects, limb reduction defects, and neural tube defects. Exposure in . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.